# Source:Latest Science News -- ScienceDaily, URL:https://www.sciencedaily.com/rss/all.xml, language:en-us

## Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer
 - [https://www.sciencedaily.com/releases/2025/01/250125152749.htm](https://www.sciencedaily.com/releases/2025/01/250125152749.htm)
 - RSS feed: $source
 - date published: 2025-01-25T15:27:49+00:00

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the PhaseIII BREAKWATER trial.

